Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.3%

8 terminated/withdrawn out of 65 trials

Success Rate

85.2%

-1.4% vs industry average

Late-Stage Pipeline

20%

13 trials in Phase 3/4

Results Transparency

78%

36 of 46 completed trials have results

Key Signals

5 recruiting36 with results8 terminated

Enrollment Performance

Analytics

Phase 2

30(55.6%)

Phase 3

13(24.1%)

N/A

6(11.1%)

Phase 1

5(9.3%)

54Total

Phase 2(30)

Phase 3(13)

N/A(6)

Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials

NCT05507827Phase 1Active Not Recruiting

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

Role: collaborator

NCT03263559Phase 2Completed

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Role: collaborator

NCT01351545Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Role: collaborator

NCT04975698Phase 2Completed

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Role: collaborator

NCT07563010Phase 2Not Yet Recruiting

Menin-Inhibitor Targeted Maintenance in AML

Role: collaborator

NCT05224661Terminated

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Role: collaborator

NCT05032820Phase 2Completed

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Role: collaborator

NCT02918292Phase 2Completed

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Role: collaborator

NCT04904588Phase 2Active Not Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Role: collaborator

NCT06859424Phase 2Recruiting

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Role: collaborator

NCT04965597Phase 2Completed

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Role: collaborator

NCT06001385Phase 2Active Not Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Role: collaborator

NCT04671797Not ApplicableCompleted

Dinner Time 2: Effect of Delayed Eating or Sleeping on Metabolism

Role: collaborator

NCT03904134Not ApplicableCompleted

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Role: collaborator

NCT02793544Phase 2Completed

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Role: collaborator

NCT03971799Phase 1Active Not Recruiting

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT02766465Phase 2Completed

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Role: collaborator

NCT00785525Phase 3Recruiting

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Role: collaborator

NCT05135650Phase 1Terminated

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Role: collaborator

NCT04762875Phase 2Terminated

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Role: collaborator